Post by PharmaShots

Mirum Pharmaceuticals, Inc. reports P-IIb (VISTAS) trial data for volixibat, showing a significant reduction in cholestatic pruritus in PSC patients, with a pre-NDA meeting planned for summer 2026 and a regulatory filing expected in 2H 2026 Subscribe to our weekly newsletter and never miss a beat: https://lnkd.in/gTU62Zbz #mirum #phaseiib #vistas #clinicaltrial #volixibat #primarysclerosingcholangitis #cholestaticpruritus #itchro #easl2026 #nda #primarybiliarycholangitis https://lnkd.in/g3NvFs2S